
XYREM PRESCRIPTION FORM

XYREM® (sodium oxybate) oral solution 0.5 g/mL



OR mail to XYWAV and XYREM REMS, PO Box 66589, St. Louis, MO 63166-6589.

For more information, call the XYWAV and XYREM REMS at 1-866-997-3688 (toll free).

Please Print (*denotes required field; †denotes required field for pediatric patients on initial fill and restarts)

Prescriber Information		
*First Name:	M.I.: *Last Name: _	
*Street Address:		*Phone:
*City:	*State: *Zip Code:	*Fax:
Office Contact:	Office Contact Phone:	*State License No.:
Patient Information		
*Indication for Use (required for initial prescription and any change in diagnosis) Select one: Cataplexy or EDS in Narcolepsy OR Cher		
*First Name:	M.I.: *Last Name:	*Primary Phone:
*Date of Birth (MM/DD/YYYY):	† Weight (if under age 18): kg *5	Sex: M F Cell Phone:
	Ţ	Work Phone:
		E-mail:
*MEDICATIONS: (list all known current p		OMORBIDITIES: (list known comorbidities or submit as a separate page)
dosages or submit as a separate page)		
*Total Quantity 1 2	3 month(s) supply (select one) Refills:	0 0 1 0 2 0 3 0 4 0 5 (select one)
Dispensing Instructions Directions: Take first dose p.o., diluted in ¼ cup of water, at bedtime. Take second dose p.o., diluted in ¼ cup of water 2.5 to 4 hours later.		
Note: Prepare both doses at the same time prior to bedtime. The XYREM shipment does not include water for dilution. Initial prescription fill cannot exceed 1 month of therapy. Refills cannot exceed 3 months supply.		
Please complete <u>EITHER</u> the titrated dosing <u>OR</u> fixed dosing section. Please see the Prescriber Brochure and the Prescribing Information for additional dosing instructions.		
Titrated XYREM Dosing: Titra		
Starting Dose: First dose: 1st Titration: First dose:		• •
1st Titration: First dose: 2nd Titration: First dose:		, · . · . · . · . · . · . · . · . ·
3rd Titration: First dose:		
First dose is ordinarily taken at bedtime; sec *For pediatric patients who sleep more than	cond dose is taken 2.5 to 4 hours later. 8 hours per night, the first dose of XYREM may be given at l	bedtime or after an initial period of sleep.
**If XYREM is used in patients 7 years of age nightly dosage should be considered. Som	e and older who weigh less than 20 kg, a lower starting dosag ne patients may achieve better responses with unequal doses	ge, lower maximum weekly dosage increases, and lower total maximum
Fixed XYREM Dosing Dose: First dose:	g + Second dose (2.5 to 4 hours later):	g = g Total Nightly Dose
Special Dosing Instructions	g second dose (2.5 to 4 nodrs later).	g lotal Nightly Dose
Special Boshig instructions		
Prescriber Verification—My signature below signifies that: I understand the statements and agree to the REMS requirements, which are found on the back of this form; XYREM is medically appropriate for this patient; and I have informed the patient and/or caregiver that the XYWAV and XYREM REMS will send him or her the appropriate educational material (XYREM Patient Quick Start Guide for adult patients and XYREM Brochure for Pediatric Patients and their Caregivers for pediatric patients) with the first prescription fill.		
Comment and Country of the For addit	satisfies and Armer is residure for registrary attents and their	careginate of pediatric patients, man the mat prescription init.
*Prescriber's signature:	OR	*Date:
	Dispense as Written	Substitution Allowed





XYREM PRESCRIPTION FORM

XYREM® (sodium oxybate) oral solution 0.5 g/mL



Prescriber: Signature verification is required on the **FRONT** page of this XYREM Prescription Form as acknowledgment that you have an understanding of and/or agree to the following:

I understand that XYREM is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.

I understand that:

- XYREM is a CNS depressant and can cause obtundation and clinically significant respiratory depression at recommended doses
- · Alcohol and sedative hypnotics are contraindicated in patients who are using XYREM
- Concurrent use of XYREM with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptics, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and death
 - If use of these CNS depressants in combination with XYREM is required, dose reduction or discontinuation of one or more CNS depressants (including XYREM) should be considered
 - If short-term use of an opioid (e.g., post- or perioperative) is required, interruption of treatment with XYREM should be considered
- Patients who have sleep apnea or compromised respiratory function (e.g., asthma, COPD, etc.) may be at higher risk of developing respiratory depression, loss of consciousness, coma, and death with XYREM use
- · XYREM is a Schedule III controlled substance with potential for abuse and misuse
- Safe use and handling by patients is important in order to prevent abuse/misuse and accidental exposure to family/friends, including children
- XYREM is to be prescribed only to patients enrolled in the XYWAV and XYREM REMS

I have read and understand the Prescribing Information and XYWAV and XYREM REMS Prescriber Brochure.

I have screened this patient for:

- · History of alcohol or substance abuse
- · History of sleep-related breathing disorders
- History of compromised respiratory function
- · Concomitant use of sedative hypnotics, other CNS depressants, or other potentially interacting agents
- · History of depression or suicidality

I have counseled this patient and/or caregiver on:

- The serious risks associated with XYREM
- Contraindications (alcohol and sedative hypnotics)
- · Risk of concomitant use of XYREM with alcohol, other CNS depressants, or other potentially interacting agents
- · Preparation and dosing instructions for XYREM
- · Risk of abuse and misuse associated with use of XYREM
- · Risk of operating hazardous machinery, including automobiles or airplanes, for the first 6 hours after taking a dose of XYREM
- · Safe use, handling, and storage of XYREM



